6 related articles for article (PubMed ID: 38726797)
1. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
[TBL] [Abstract][Full Text] [Related]
3. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Apr; ():. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
4.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
5.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
6.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
